FY2025 EPS Estimates for SLNO Reduced by Cantor Fitzgerald

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Investment analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Soleno Therapeutics in a report released on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now expects that the company will earn ($2.65) per share for the year, down from their previous estimate of ($1.97). The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.41).

Other equities research analysts have also recently issued research reports about the company. Stifel Nicolaus initiated coverage on Soleno Therapeutics in a research note on Wednesday. They set a “buy” rating and a $74.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of Soleno Therapeutics in a research report on Monday. Robert W. Baird reissued an “outperform” rating and set a $72.00 target price on shares of Soleno Therapeutics in a research note on Monday, December 2nd. Finally, Lifesci Capital raised Soleno Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 4th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $71.20.

Soleno Therapeutics Stock Down 0.1 %

Shares of NASDAQ SLNO opened at $44.94 on Thursday. The company has a market capitalization of $1.94 billion, a PE ratio of -13.54 and a beta of -1.46. Soleno Therapeutics has a twelve month low of $36.61 and a twelve month high of $60.92. The firm has a fifty day simple moving average of $47.16 and a 200 day simple moving average of $49.83.

Insider Activity

In other news, insider Kristen Yen sold 2,340 shares of the stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $46.18, for a total value of $108,061.20. Following the completion of the sale, the insider now owns 76,605 shares in the company, valued at $3,537,618.90. This represents a 2.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bhatnagar Anish sold 10,937 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total transaction of $496,649.17. Following the transaction, the chief executive officer now directly owns 708,616 shares in the company, valued at $32,178,252.56. The trade was a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 17,360 shares of company stock worth $790,119 over the last 90 days. 12.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Soleno Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC boosted its position in Soleno Therapeutics by 27.1% in the fourth quarter. Janus Henderson Group PLC now owns 5,188,265 shares of the company’s stock worth $233,130,000 after purchasing an additional 1,107,166 shares during the last quarter. FMR LLC boosted its holdings in shares of Soleno Therapeutics by 6,048,754.5% in the 3rd quarter. FMR LLC now owns 665,374 shares of the company’s stock worth $33,595,000 after buying an additional 665,363 shares during the last quarter. Nantahala Capital Management LLC grew its position in Soleno Therapeutics by 20.1% during the fourth quarter. Nantahala Capital Management LLC now owns 3,928,966 shares of the company’s stock valued at $176,607,000 after buying an additional 658,518 shares during the period. Westfield Capital Management Co. LP bought a new position in Soleno Therapeutics during the third quarter valued at about $25,028,000. Finally, Avoro Capital Advisors LLC raised its position in Soleno Therapeutics by 15.8% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,525,000 shares of the company’s stock worth $113,499,000 after acquiring an additional 344,000 shares during the period. 97.42% of the stock is owned by hedge funds and other institutional investors.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.